Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing
new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and
how safe Patidegib Gel 2% is to use.
Participants will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug
substance) to their face twice a day for a year (12 months). The number of new BCCs on the
face will be compared between participants who used Patidegib Gel 2% or Vehicle Gel after 12
months.